SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oncothyreon
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Nonos who wrote (2275)8/25/2013 7:45:35 PM
From: scaram(o)uche  Read Replies (1) of 2344
 
Jim:

Cyclophosphamide... don't know. I'd say that it looks obvious in 2013, but not when START got off ground? It was such a difficult trial to run, I think that Merck's personnel are heroes and that the vision of Merck's executives is pretty cool. Glad someone took this shot, after reviewing the preclinical stuff (including some from Red et al.).

So, regardless of which direction the vaccine takes now? A huge thanks is due to everyone who contributed to this regal study.

Tregs.... Guffaw. If you look at my original post, that's exactly the point where I said (paraphrasing) "something happens".

:-)

I don't understand either, but I'm interested in what is known about relative timing of chemo to radiation and effects on T cell subsets. Also interested in any info re. chemo alone, effects on Treg. Don't know this stuff.

Dr. Butts has to be all over that, as Merck would be. That's why I'm interested in the sCRT group, for what it might tell us.

Thanks again.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News